Truvada, not Descovy, should be the first choice for PrEP, US experts say
Serosorting between gay men may be in decline as ‘PrEP sorting’ rises, Canadian study finds
How do we deal with apparent cases of PrEP failure?
96-week results of DISCOVER PrEP trial presented at European AIDS Conference
French study finds one in six stops PrEP within 12 months, one in three after 30 months
Switching to TAF-based PrEP improves kidney and bone markers – but does it raise cardiovascular risk?
US FDA approves TAF-based PrEP for many people at risk for HIV
PrEP is reducing HIV diagnoses in US cities, independently of the effect of treatment
Does Descovy have a role as PrEP in people who struggle with adherence?
